{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:03:03Z","timestamp":1790096583986,"version":"4.0.1"},"reference-count":219,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"DOI":"10.1007\/s13346-026-02222-6","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:48:17Z","timestamp":1790088497000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Smart drug delivery systems for immunotherapeutic agents: focus on biological\/biogenic platform-based intelligent delivery in cancer immunotherapy"],"prefix":"10.1007","author":[{"given":"Parisa","family":"Abbasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvin","family":"AfsharManesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samaneh","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojtaba","family":"Mozdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parisa","family":"Shakeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloofar","family":"Khandan-Nasab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davood","family":"Zaeifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2173-003X","authenticated-orcid":false,"given":"Khadijeh","family":"Jamialahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9166-2939","authenticated-orcid":false,"given":"Reza Kazemi","family":"Oskuee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"issue":"9","key":"2222_CR1","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.3390\/cancers17091408","volume":"17","author":"V Mc Neil","year":"2025","unstructured":"Mc Neil V, Lee SW. Advancing Cancer Treatment: A Review of Immune Checkpoint Inhibitors and Combination Strategies. Cancers. 2025;17(9):1408.","journal-title":"Cancers"},{"issue":"22","key":"2222_CR2","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","volume":"332","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Maus MV, Hinrichs CS. CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review. JAMA. 2024;332(22):1924\u201335.","journal-title":"JAMA"},{"issue":"24","key":"2222_CR3","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.3390\/cells12242837","volume":"12","author":"M Delgado","year":"2023","unstructured":"Delgado M, Garcia-Sanz JA. Therapeutic Monoclonal Antibodies against Cancer: Present and Future. Cells. 2023;12(24):2837.","journal-title":"Cells"},{"issue":"7662","key":"2222_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217\u201321.","journal-title":"Nature"},{"issue":"12","key":"2222_CR5","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","volume":"192","author":"SA Rosenberg","year":"2014","unstructured":"Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192(12):5451\u20138.","journal-title":"J Immunol"},{"issue":"25","key":"2222_CR6","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015;33(25):2780\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2222_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378(2):158\u201368.","journal-title":"N Engl J Med"},{"issue":"10","key":"2222_CR8","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.2703","volume":"14","author":"TF Gajewski","year":"2013","unstructured":"Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014\u201322.","journal-title":"Nat Immunol"},{"issue":"8","key":"2222_CR9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"5","key":"2222_CR10","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/clpt.2008.170","volume":"84","author":"W Wang","year":"2008","unstructured":"Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548\u201358.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2222_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/imm.13793","volume":"173","author":"Z-B Wang","year":"2024","unstructured":"Wang Z-B, Zhang X, Fang C, Liu X-T, Liao Q-J, Wu N, et al. Immunotherapy and the ovarian cancer microenvironment: Exploring potential strategies for enhanced treatment efficacy. Immunology. 2024;173(1):14\u201332.","journal-title":"Immunology"},{"issue":"10","key":"2222_CR12","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1038\/s41588-024-01899-0","volume":"56","author":"J Usset","year":"2024","unstructured":"Usset J, Rosendahl Huber A, Andrianova MA, Batlle E, Carles J, Cuppen E, et al. Five latent factors underlie response to immunotherapy. Nat Genet. 2024;56(10):2112\u201320.","journal-title":"Nat Genet"},{"issue":"7","key":"2222_CR13","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1007\/s00262-023-03441-3","volume":"72","author":"Y Mao","year":"2023","unstructured":"Mao Y, Xie H, Lv M, Yang Q, Shuang Z, Gao F, et al. The landscape of objective response rate of anti-PD-1\/L1 monotherapy across 31 types of cancer: a system review and novel biomarker investigating. Cancer Immunol Immunother. 2023;72(7):2483\u201398.","journal-title":"Cancer Immunol Immunother"},{"key":"2222_CR14","unstructured":"Food US, Drug A. BAVENCIO (avelumab) injection, for intravenous use: Prescribing Information. U.S. Food and Drug Administration; 2023."},{"issue":"1","key":"2222_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s13346-023-01405-9","volume":"14","author":"E P\u00e9rez-Herrero","year":"2024","unstructured":"P\u00e9rez-Herrero E, Lanier OL, Krishnan N, D\u2019Andrea A, Peppas NA. Drug delivery methods for cancer immunotherapy. Drug Deliv Transl Res. 2024;14(1):30\u201361.","journal-title":"Drug Deliv Transl Res"},{"key":"2222_CR16","doi-asserted-by":"publisher","first-page":"650587","DOI":"10.3389\/fchem.2021.650587","volume":"9","author":"Y Li","year":"2021","unstructured":"Li Y, Yang J, Sun X. Reactive Oxygen Species-Based Nanomaterials for Cancer Therapy. Front Chem. 2021;9:650587.","journal-title":"Front Chem"},{"key":"2222_CR17","doi-asserted-by":"publisher","first-page":"13193","DOI":"10.1038\/ncomms13193","volume":"7","author":"Q Chen","year":"2016","unstructured":"Chen Q, Xu L, Liang C, Wang C, Peng R, Liu Z. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. Nat Commun. 2016;7:13193.","journal-title":"Nat Commun"},{"issue":"6478","key":"2222_CR18","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1126\/science.aau6977","volume":"367","author":"R Kalluri","year":"2020","unstructured":"Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):0\u20130. https:\/\/doi.org\/10.1126\/science.aau6977","journal-title":"Science"},{"key":"2222_CR19","doi-asserted-by":"publisher","first-page":"5837","DOI":"10.2147\/IJN.S466042","volume":"19","author":"Y Wang","year":"2024","unstructured":"Wang Y, Xu Y, Song J, Liu X, Liu S, Yang N, et al. Tumor Cell-Targeting and Tumor Microenvironment-Responsive Nanoplatforms for the Multimodal Imaging-Guided Photodynamic\/Photothermal\/Chemodynamic Treatment of Cervical Cancer. Int J Nanomed. 2024;19:5837\u201358.","journal-title":"Int J Nanomed"},{"key":"2222_CR20","doi-asserted-by":"publisher","first-page":"101126","DOI":"10.1016\/j.mser.2025.101126","volume":"167","author":"C Lin","year":"2026","unstructured":"Lin C, Yang M, Zhang F, Liu Y, Leng J. Stimuli-responsive smart materials for biomedical applications. Mater Sci Engineering: R: Rep. 2026;167:101126.","journal-title":"Mater Sci Engineering: R: Rep"},{"key":"2222_CR21","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.2147\/IJN.S225807","volume":"15","author":"Y Hei","year":"2020","unstructured":"Hei Y, Teng B, Zeng Z, Zhang S, Li Q, Pan J, et al. Multifunctional Immunoliposomes Combining Catalase and PD-L1 Antibodies Overcome Tumor Hypoxia and Enhance Immunotherapeutic Effects Against Melanoma. Int J Nanomed. 2020;15:1677\u201391.","journal-title":"Int J Nanomed"},{"issue":"9","key":"2222_CR22","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1158\/1078-0432.CCR-18-1811","volume":"25","author":"Y Chen","year":"2019","unstructured":"Chen Y, Sun C, Landoni E, Metelitsa L, Dotti G, Savoldo B. Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15. Clin Cancer Res. 2019;25(9):2915\u201324.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2222_CR23","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/s43018-020-00119-y","volume":"1","author":"K Wang","year":"2020","unstructured":"Wang K, Chen Y, Ahn S, Zheng M, Landoni E, Dotti G, et al. GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision. Nat Cancer. 2020;1(10):990\u20137.","journal-title":"Nat Cancer"},{"issue":"24","key":"2222_CR24","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.3390\/cancers17243978","volume":"17","author":"NL Mangang","year":"2025","unstructured":"Mangang NL, Gargasz SK, Murugan SG, Kumar M, Shukla GC, Vijayaraghavalu S. MicroRNAs Modulating Cancer Immunotherapy Mechanisms and Therapeutic Synergies. Cancers. 2025;17(24):3978.","journal-title":"Cancers"},{"issue":"11","key":"2222_CR25","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","volume":"122","author":"DS Hong","year":"2020","unstructured":"Hong DS, Kang Y-K, Borad M, Sachdev J, Ejadi S, Lim HY, et al. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020;122(11):1630\u20137.","journal-title":"Br J Cancer"},{"issue":"1","key":"2222_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s12276-023-01132-8","volume":"56","author":"I Jung","year":"2024","unstructured":"Jung I, Shin S, Baek MC, Yea K. Modification of immune cell-derived exosomes for enhanced cancer immunotherapy: current advances and therapeutic applications. Exp Mol Med. 2024;56(1):19\u201331.","journal-title":"Exp Mol Med"},{"key":"2222_CR27","doi-asserted-by":"publisher","first-page":"108493","DOI":"10.1016\/j.intimp.2021.108493","volume":"104","author":"A Asadirad","year":"2022","unstructured":"Asadirad A, Baghaei K, Hashemi SM, Dehnavi S, Ghanbarian H, Mortaz E, et al. Dendritic cell immunotherapy with miR-155 enriched tumor-derived exosome suppressed cancer growth and induced antitumor immune responses in murine model of colorectal cancer induced by CT26 cell line. Int Immunopharmacol. 2022;104:108493.","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"2222_CR28","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1002\/jbm.a.36515","volume":"106","author":"B Yu","year":"2018","unstructured":"Yu B, Song N, Hu H, Chen G, Shen Y, Cong H. A degradable triple temperature-, pH\u2010, and redox\u2010responsive drug system for cancer chemotherapy. J Biomedical Mater Res Part A. 2018;106(12):3203\u201310.","journal-title":"J Biomedical Mater Res Part A"},{"issue":"3","key":"2222_CR29","first-page":"138","volume":"2","author":"NM Mohammadi","year":"2025","unstructured":"Mohammadi NM. Biopolymers As Smart Drug Carriers in Cancer Therapy: Innovations and Perspectives. Biocompounds. 2025;2(3):138\u201350.","journal-title":"Biocompounds"},{"issue":"1","key":"2222_CR30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/iwj.13248","volume":"17","author":"S Rabiee Motmaen","year":"2020","unstructured":"Rabiee Motmaen S, Tavakol S, Joghataei MT, Barati M. Acidic pH derived from cancer cells as a double-edged knife modulates wound healing through DNA repair genes and autophagy. Int Wound J. 2020;17(1):137\u201348.","journal-title":"Int Wound J"},{"key":"2222_CR31","doi-asserted-by":"publisher","first-page":"110824","DOI":"10.1016\/j.matdes.2022.110824","volume":"219","author":"K Guo","year":"2022","unstructured":"Guo K, Liu Y, Ding M, Sun Q, Shubhra QT. Enhanced drug release from a pH-responsive nanocarrier can augment colon cancer treatment by blocking PD-L1 checkpoint and consuming tumor glucose. Mater Design. 2022;219:110824.","journal-title":"Mater Design"},{"issue":"12","key":"2222_CR32","doi-asserted-by":"publisher","first-page":"6270","DOI":"10.1021\/acs.molpharmaceut.4c00723","volume":"21","author":"KS Maravajjala","year":"2024","unstructured":"Maravajjala KS, Paul M, Jaiswal R, Verma V, Biswas S, Roy A. Synergistic Chemo-Immunotherapy Using pH-Responsive Nanoparticles in Breast Cancer Treatment: In Vitro and In Vivo Studies. Mol Pharm. 2024;21(12):6270\u201389.","journal-title":"Mol Pharm"},{"issue":"10","key":"2222_CR33","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.3390\/biom10101429","volume":"10","author":"L Kennedy","year":"2020","unstructured":"Kennedy L, Sandhu JK, Harper M-E, Cuperlovic-Culf M. Role of glutathione in cancer: from mechanisms to therapies. Biomolecules. 2020;10(10):1429.","journal-title":"Biomolecules"},{"issue":"35","key":"2222_CR34","doi-asserted-by":"publisher","first-page":"2301148","DOI":"10.1002\/smll.202301148","volume":"19","author":"WF Song","year":"2023","unstructured":"Song WF, Zeng JY, Ji P, Han ZY, Sun YX, Zhang XZ. Self-assembled copper\u2010based nanoparticles for glutathione activated and enzymatic cascade\u2010enhanced ferroptosis and immunotherapy in cancer treatment. Small. 2023;19(35):2301148.","journal-title":"Small"},{"issue":"1","key":"2222_CR35","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41467-024-55658-0","volume":"16","author":"J Zou","year":"2025","unstructured":"Zou J, Jiang C, Hu Q, Jia X, Wang S, Wan S, et al. Tumor microenvironment-responsive engineered hybrid nanomedicine for photodynamic-immunotherapy via multi-pronged amplification of reactive oxygen species. Nat Commun. 2025;16(1):424.","journal-title":"Nat Commun"},{"issue":"10","key":"2222_CR36","doi-asserted-by":"publisher","first-page":"5803","DOI":"10.1021\/jacs.2c12942","volume":"145","author":"P Zhu","year":"2023","unstructured":"Zhu P, Pu Y, Wang M, Wu W, Qin H, Shi J. MnOOH-catalyzed autoxidation of glutathione for reactive oxygen species production and nanocatalytic tumor innate immunotherapy. J Am Chem Soc. 2023;145(10):5803\u201315.","journal-title":"J Am Chem Soc"},{"issue":"7","key":"2222_CR37","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11538-021-00914-3","volume":"83","author":"G Fiandaca","year":"2021","unstructured":"Fiandaca G, Delitala M, Lorenzi T. A mathematical study of the influence of hypoxia and acidity on the evolutionary dynamics of cancer. Bull Math Biol. 2021;83(7):83.","journal-title":"Bull Math Biol"},{"issue":"1","key":"2222_CR38","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1158\/0008-5472.CAN-23-1038","volume":"84","author":"X Zhu","year":"2024","unstructured":"Zhu X, Chen J, Li W, Xu Y, Shan J, Hong J, et al. Hypoxia-responsive CAR-T cells exhibit reduced exhaustion and enhanced efficacy in solid tumors. Cancer Res. 2024;84(1):84\u2013100.","journal-title":"Cancer Res"},{"key":"2222_CR39","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.actbio.2022.06.026","volume":"148","author":"K Sun","year":"2022","unstructured":"Sun K, Yu J, Hu J, Chen J, Song J, Chen Z, et al. Salicylic acid-based hypoxia-responsive chemodynamic nanomedicines boost antitumor immunotherapy by modulating immunosuppressive tumor microenvironment. Acta Biomater. 2022;148:230\u201343.","journal-title":"Acta Biomater"},{"key":"2222_CR40","doi-asserted-by":"publisher","unstructured":"Zhou S, Zhang Q, Han H, Chen G, Wang P, Xue S, et al. Hypoxia-activated paclitaxel prodrugs enable PD-L1 degradation to potentiate cancer chemo-immunotherapy. J Nanobiotechnol. 2025;24(1):18. https:\/\/doi.org\/10.1186\/s12951-025-03894-x","DOI":"10.1186\/s12951-025-03894-x"},{"issue":"1","key":"2222_CR41","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10238-021-00733-9","volume":"22","author":"S Albhaisi","year":"2022","unstructured":"Albhaisi S, Qayyum R. The association between serum liver enzymes and cancer mortality. Clin experimental Med. 2022;22(1):75\u201381.","journal-title":"Clin experimental Med"},{"issue":"2","key":"2222_CR42","doi-asserted-by":"publisher","first-page":"2306230","DOI":"10.1002\/advs.202306230","volume":"11","author":"X Song","year":"2024","unstructured":"Song X, Cai H, Shi Z, Li Z, Zheng X, Yang K, et al. Enzyme-Responsive Branched Glycopolymer\u2010Based Nanoassembly for Co\u2010Delivery of Paclitaxel and Akt Inhibitor toward Synergistic Therapy of Gastric Cancer. Adv Sci. 2024;11(2):2306230.","journal-title":"Adv Sci"},{"issue":"22","key":"2222_CR43","doi-asserted-by":"publisher","first-page":"14145","DOI":"10.1021\/acsnano.3c03409","volume":"18","author":"P Dosta","year":"2024","unstructured":"Dosta P, Dion MZ, Prado M, Hurtado P, Riojas-Javelly CJ, Cryer AM, et al. Matrix metalloproteinase-and pH-sensitive nanoparticle system enhances drug retention and penetration in glioblastoma. ACS Nano. 2024;18(22):14145\u201360.","journal-title":"ACS Nano"},{"issue":"5","key":"2222_CR44","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.7150\/thno.53056","volume":"11","author":"M Wang","year":"2021","unstructured":"Wang M, Rao J, Wang M, Li X, Liu K, Naylor MF, et al. Cancer photo-immunotherapy: from bench to bedside. Theranostics. 2021;11(5):2218.","journal-title":"Theranostics"},{"issue":"1","key":"2222_CR45","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41377-025-01757-6","volume":"14","author":"Q Cheng","year":"2025","unstructured":"Cheng Q, Wang Q, Qu S. Photon-triggered pyroptosis and ferroptosis dual-functional nanoplatform for cancer immunotherapy. Light: Sci Appl. 2025;14(1):104.","journal-title":"Light: Sci Appl"},{"key":"2222_CR46","doi-asserted-by":"publisher","first-page":"137688","DOI":"10.1016\/j.jcis.2025.137688","volume":"694","author":"X Hu","year":"2025","unstructured":"Hu X, Shen Z, Hao H, Ma K, Zhen A, Yang Y, et al. NIR II light-driven nanomotor synergistically enhances immunogenic cell death through photothermal and chemodynamic therapy for melanoma immunotherapy. J Colloid Interface Sci. 2025;694:137688. https:\/\/doi.org\/10.1016\/j.jcis.2025.137688","journal-title":"J Colloid Interface Sci"},{"key":"2222_CR47","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.aej.2025.06.022","volume":"129","author":"M Moradialvand","year":"2025","unstructured":"Moradialvand M, Farashi S, Dey AD, Kumar A, Sharifi I, Hassanpour M, et al. Cell fate regulation by hyperthermia: Cancer, stem cells, and immune system. Alexandria Eng J. 2025;129:240\u201354.","journal-title":"Alexandria Eng J"},{"issue":"2","key":"2222_CR48","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3390\/pharmaceutics17020166","volume":"17","author":"G Jiang","year":"2025","unstructured":"Jiang G, Huang R, Qian M, Hu W, Huang R. IR813-Induced Photothermal Therapy: Leveraging Immunogenic Cell Death for Cancer Treatment. Pharmaceutics. 2025;17(2):166.","journal-title":"Pharmaceutics"},{"key":"2222_CR49","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.actbio.2016.12.004","volume":"51","author":"Y Chen","year":"2017","unstructured":"Chen Y, Li H, Deng Y, Sun H, Ke X, Ci T. Near-infrared light triggered drug delivery system for higher efficacy of combined chemo-photothermal treatment. Acta Biomater. 2017;51:374\u201392.","journal-title":"Acta Biomater"},{"key":"2222_CR50","doi-asserted-by":"publisher","first-page":"100248","DOI":"10.1016\/j.mtadv.2022.100248","volume":"14","author":"S Sun","year":"2022","unstructured":"Sun S, Tang Q, Sun L, Zhang J, Zhang L, Xu M, et al. Ultrasound-mediated immune regulation in tumor immunotherapy. Mater Today Adv. 2022;14:100248.","journal-title":"Mater Today Adv"},{"issue":"7","key":"2222_CR51","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1016\/j.apsb.2025.05.006","volume":"15","author":"X Li","year":"2025","unstructured":"Li X, Wu J, Xu R, Qin X, Wang S, Yang W, et al. High intensity forced ultrasound-driven ferroptosis as a strategy for anti-tumor immune priming. Acta Pharm Sinica B. 2025;15(7):3788\u2013804. https:\/\/doi.org\/10.1016\/j.apsb.2025.05.006","journal-title":"Acta Pharm Sinica B"},{"issue":"1","key":"2222_CR52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40824-023-00350-5","volume":"27","author":"J Zheng","year":"2023","unstructured":"Zheng J, Huang J, Zhang L, Wang M, Xu L, Dou X, et al. Drug-loaded microbubble delivery system to enhance PD-L1 blockade immunotherapy with remodeling immune microenvironment. Biomaterials Res. 2023;27(1):9.","journal-title":"Biomaterials Res"},{"key":"2222_CR53","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.2147\/IJN.S376172","volume":"17","author":"Y Chen","year":"2022","unstructured":"Chen Y, Luo X, Liu Y, Zou Y, Yang S, Liu C, et al. Targeted nanobubbles of PD-L1 mAb combined with doxorubicin as a synergistic tumor repressor in hepatocarcinoma. Int J Nanomed. 2022;17:3989.","journal-title":"Int J Nanomed"},{"issue":"8","key":"2222_CR54","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1016\/j.apsb.2021.03.023","volume":"11","author":"NB Day","year":"2021","unstructured":"Day NB, Wixson WC, Shields IVCW. Magnetic systems for cancer immunotherapy. Acta Pharm Sinica B. 2021;11(8):2172\u201396.","journal-title":"Acta Pharm Sinica B"},{"issue":"11","key":"2222_CR55","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.7150\/thno.15102","volume":"6","author":"H Jin","year":"2016","unstructured":"Jin H, Qian Y, Dai Y, Qiao S, Huang C, Lu L, et al. Magnetic enrichment of dendritic cell vaccine in lymph node with fluorescent-magnetic nanoparticles enhanced cancer immunotherapy. Theranostics. 2016;6(11):2000.","journal-title":"Theranostics"},{"key":"2222_CR56","doi-asserted-by":"publisher","first-page":"119370","DOI":"10.1016\/j.biomaterials.2019.119370","volume":"219","author":"Y Guo","year":"2019","unstructured":"Guo Y, Ran Y, Wang Z, Cheng J, Cao Y, Yang C, et al. Magnetic-responsive and targeted cancer nanotheranostics by PA\/MR bimodal imaging-guided photothermally triggered immunotherapy. Biomaterials. 2019;219:119370.","journal-title":"Biomaterials"},{"key":"2222_CR57","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jconrel.2024.12.009","volume":"378","author":"L Huang","year":"2025","unstructured":"Huang L, Zhang Q, Long J, Liu Z, Sun X. Construction of novel magnetic systems for cancer immunotherapy via cancer-immunity cycle circuits. J Controlled Release. 2025;378:38\u201359.","journal-title":"J Controlled Release"},{"issue":"5","key":"2222_CR58","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3390\/pharmaceutics16050674","volume":"16","author":"Q Chen","year":"2024","unstructured":"Chen Q, Yang Z, Liu H, Man J, Oladejo AO, Ibrahim S, et al. Novel Drug Delivery Systems: An Important Direction for Drug Innovation Research and Development. Pharmaceutics. 2024;16(5):674.","journal-title":"Pharmaceutics"},{"key":"2222_CR59","first-page":"1","volume-title":"Next-Generation Drug Delivery Systems","author":"S Pal","year":"2025","unstructured":"Pal S, Naveen D, Tejpal, Debroy S. Introduction to Drug Delivery System: Past, Present, and Future Perspectives. In: Pathak A, Singh SP, editors. Next-Generation Drug Delivery Systems. New York, NY: Springer US; 2025. pp. 1\u201328."},{"key":"2222_CR60","doi-asserted-by":"publisher","first-page":"102930","DOI":"10.1016\/j.cis.2023.102930","volume":"317","author":"S Kans\u0131z","year":"2023","unstructured":"Kans\u0131z S, El\u00e7in YM. Advanced liposome and polymersome-based drug delivery systems: Considerations for physicochemical properties, targeting strategies and stimuli-sensitive approaches. Adv Colloid Interface Sci. 2023;317:102930.","journal-title":"Adv Colloid Interface Sci"},{"issue":"23","key":"2222_CR61","doi-asserted-by":"publisher","first-page":"5933","DOI":"10.1039\/D4BM00995A","volume":"12","author":"I Oliveira","year":"2024","unstructured":"Oliveira I, Rodrigues-Santos P, Ferreira L. Pires das Neves R. Synthetic and biological nanoparticles for cancer immunotherapy. Biomaterials Sci. 2024;12(23):5933\u201360.","journal-title":"Biomaterials Sci"},{"issue":"1","key":"2222_CR62","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1208\/s12248-015-9843-4","volume":"18","author":"S Bobbala","year":"2016","unstructured":"Bobbala S, Tamboli V, McDowell A, Mitra AK, Hook S. Novel Injectable Pentablock Copolymer Based Thermoresponsive Hydrogels for Sustained Release Vaccines. Aaps j. 2016;18(1):261\u20139.","journal-title":"Aaps j"},{"issue":"10","key":"2222_CR63","first-page":"3036","volume":"6","author":"F Yang","year":"2021","unstructured":"Yang F, Shi K, Hao Y, Jia Y, Liu Q, Chen Y, et al. Cyclophosphamide loaded thermo-responsive hydrogel system synergize with a hydrogel cancer vaccine to amplify cancer immunotherapy in a prime-boost manner. Bioact Mater. 2021;6(10):3036\u201348.","journal-title":"Bioact Mater"},{"key":"2222_CR64","doi-asserted-by":"publisher","first-page":"100209","DOI":"10.1016\/j.nxnano.2025.100209","volume":"8","author":"R Chelliah","year":"2025","unstructured":"Chelliah R, Rubab M, Vijayalakshmi S, Karuvelan M, Barathikannan K, Oh D-H. Liposomes for drug delivery: Classification, therapeutic applications, and limitations. Next Nanatechnol. 2025;8:100209.","journal-title":"Next Nanatechnol"},{"key":"2222_CR65","doi-asserted-by":"publisher","first-page":"101801","DOI":"10.1016\/j.mtbio.2025.101801","volume":"32","author":"S Lu","year":"2025","unstructured":"Lu S, Zhang C, Wu H, Wang J, Wang J, Zhao L, et al. A pH\/MMP-9 smart dual-responsive liposome GBE@LP co-delivers and controls the release of GB1107\/BMS1166\/Enzalutamide for liver cancer immunotherapy. Mater Today Bio. 2025;32:101801.","journal-title":"Mater Today Bio"},{"key":"2222_CR66","doi-asserted-by":"publisher","unstructured":"Lee Y, Thompson DH. Stimuli-responsive liposomes for drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017;9(5), p.e1450. https:\/\/doi.org\/10.1002\/wnan.1450","DOI":"10.1002\/wnan.1450"},{"issue":"4","key":"2222_CR67","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3390\/micro4040051","volume":"4","author":"IF Almadani","year":"2024","unstructured":"Almadani IF, Almadani MF, AlSawaftah N, Abuwatfa WH, Husseini GA. Nanocarriers Responsive to Light\u2014A Review. Micro. 2024;4(4):827\u201344.","journal-title":"Micro"},{"key":"2222_CR68","doi-asserted-by":"publisher","first-page":"1031811","DOI":"10.3389\/fchem.2022.1031811","volume":"10","author":"F Wang","year":"2022","unstructured":"Wang F, Duan H, Xu W, Sheng G, Sun Z, Chu H. Light-activated nanomaterials for tumor immunotherapy. Front Chem. 2022;10:1031811.","journal-title":"Front Chem"},{"issue":"1","key":"2222_CR69","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s12951-021-01125-7","volume":"19","author":"LL Bu","year":"2021","unstructured":"Bu LL, Wang HQ, Pan Y, Chen L, Wu H, Wu X, et al. Gelatinase-sensitive nanoparticles loaded with photosensitizer and STAT3 inhibitor for cancer photothermal therapy and immunotherapy. J Nanobiotechnol. 2021;19(1):379.","journal-title":"J Nanobiotechnol"},{"issue":"7","key":"2222_CR70","doi-asserted-by":"publisher","first-page":"2007293","DOI":"10.1002\/adma.202007293","volume":"33","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Ma S, Liu X, Xu Y, Zhao J, Si X, et al. Supramolecular Assembled Programmable Nanomedicine As In Situ Cancer Vaccine for Cancer Immunotherapy. Adv Mater. 2021;33(7):2007293.","journal-title":"Adv Mater"},{"issue":"24","key":"2222_CR71","doi-asserted-by":"publisher","first-page":"2210986","DOI":"10.1002\/adma.202210986","volume":"35","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Liu Y, Wu Z, Peng C, Wang Z, Yan J, et al. Photoallosteric Polymersomes toward On-Demand Drug Delivery and Multimodal Cancer Immunotherapy. Adv Mater. 2023;35(24):2210986.","journal-title":"Adv Mater"},{"key":"2222_CR72","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jcis.2023.01.091","volume":"637","author":"J Zhou","year":"2023","unstructured":"Zhou J, Li K, Qin H, Xie B, Liao H, Su X, et al. Programmed-stimuli responsive carrier-free multidrug delivery system for highly efficient trimodal combination therapy. J Colloid Interface Sci. 2023;637:453\u201364.","journal-title":"J Colloid Interface Sci"},{"issue":"4","key":"2222_CR73","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41571-025-01000-6","volume":"22","author":"SW Linderman","year":"2025","unstructured":"Linderman SW, DeRidder L, Sanjurjo L, Foote MB, Alonso MJ, Kirtane AR, et al. Enhancing immunotherapy with tumour-responsive nanomaterials. Nat Reviews Clin Oncol. 2025;22(4):262\u201382.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"1","key":"2222_CR74","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12943-025-02372-0","volume":"24","author":"JJJ Liu","year":"2025","unstructured":"Liu JJJ, Liu D, To SKY, Wong AST. Exosomes in cancer nanomedicine: biotechnological advancements and innovations. Mol Cancer. 2025;24(1):166.","journal-title":"Mol Cancer"},{"issue":"1","key":"2222_CR75","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13046-025-03403-w","volume":"44","author":"Z Gong","year":"2025","unstructured":"Gong Z, Cheng C, Sun C, Cheng X. Harnessing engineered extracellular vesicles for enhanced therapeutic efficacy: advancements in cancer immunotherapy. J Experimental Clin Cancer Res. 2025;44(1):138.","journal-title":"J Experimental Clin Cancer Res"},{"issue":"7","key":"2222_CR76","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3390\/nano14070639","volume":"14","author":"V Poinsot","year":"2024","unstructured":"Poinsot V, Pizzinat N, Ong-Meang V. Engineered and Mimicked Extracellular Nanovesicles for Therapeutic Delivery. Nanomaterials. 2024;14(7):639.","journal-title":"Nanomaterials"},{"issue":"10","key":"2222_CR77","doi-asserted-by":"publisher","first-page":"5960","DOI":"10.1021\/acsbiomaterials.4c00856","volume":"10","author":"W Ahmed","year":"2024","unstructured":"Ahmed W, Mushtaq A, Ali S, Khan N, Liang Y, Duan L. Engineering Approaches for Exosome Cargo Loading and Targeted Delivery: Biological versus Chemical Perspectives. ACS Biomaterials Sci Eng. 2024;10(10):5960\u201376.","journal-title":"ACS Biomaterials Sci Eng"},{"issue":"8","key":"2222_CR78","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1039\/D3NH00061C","volume":"8","author":"G Jiang","year":"2023","unstructured":"Jiang G, Xiang Z, Fang Q. Engineering magnetotactic bacteria MVs to synergize chemotherapy, ferroptosis and immunotherapy for augmented antitumor therapy. Nanoscale Horizons. 2023;8(8):1062\u201372.","journal-title":"Nanoscale Horizons"},{"issue":"9","key":"2222_CR79","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.20892\/j.issn.2095-3941.2022.0452","volume":"19","author":"X Gao","year":"2022","unstructured":"Gao X, Feng Q, Wang J, Zhao X. Bacterial outer membrane vesicle-based cancer nanovaccines. Cancer Biol Med. 2022;19(9):1290\u2013300.","journal-title":"Cancer Biol Med"},{"key":"2222_CR80","doi-asserted-by":"publisher","first-page":"100029","DOI":"10.1016\/j.vesic.2023.100029","volume":"2","author":"K Cheng","year":"2023","unstructured":"Cheng K, Kalluri R. Guidelines for clinical translation and commercialization of extracellular vesicles and exosomes based therapeutics. Extracell Vesicle. 2023;2:100029.","journal-title":"Extracell Vesicle"},{"issue":"2","key":"2222_CR81","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0022-1759(02)00330-7","volume":"270","author":"HG Lamparski","year":"2002","unstructured":"Lamparski HG, Metha-Damani A, Yao J-Y, Patel S, Hsu D-H, Ruegg C, et al. Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods. 2002;270(2):211\u201326.","journal-title":"J Immunol Methods"},{"key":"2222_CR82","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jconrel.2022.04.029","volume":"346","author":"Z Qi","year":"2022","unstructured":"Qi Z, Pei P, Zhang Y, Chen H, Yang S, Liu T, et al. (131)I-\u03b1PD-L1 immobilized by bacterial cellulose for enhanced radio-immunotherapy of cancer. J Control Release. 2022;346:240\u20139.","journal-title":"J Control Release"},{"key":"2222_CR83","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jconrel.2022.04.038","volume":"347","author":"X Wang","year":"2022","unstructured":"Wang X, Lu J, Mao Y, Zhao Q, Chen C, Han J, et al. A mutually beneficial macrophages-mediated delivery system realizing photo\/immune therapy. J Control Release. 2022;347:14\u201326.","journal-title":"J Control Release"},{"key":"2222_CR84","first-page":"55","volume":"38","author":"Q Guo","year":"2024","unstructured":"Guo Q, Qian ZM. Macrophage based drug delivery: Key challenges and strategies. Bioact Mater. 2024;38:55\u201372.","journal-title":"Bioact Mater"},{"key":"2222_CR85","doi-asserted-by":"publisher","first-page":"12323","DOI":"10.2147\/IJN.S481368","volume":"19","author":"J Wu","year":"2024","unstructured":"Wu J, Shi K, Chao W, Qin Z, Hu Y, Yang Y, et al. Artificially Modified NK Cell-Based Synergistic Immuno-Gene-Photodynamic Therapy for Cancer. Int J Nanomed. 2024;19:12323\u201342.","journal-title":"Int J Nanomed"},{"key":"2222_CR86","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jconrel.2023.09.007","volume":"362","author":"S Huang","year":"2023","unstructured":"Huang S, Xing F, Dai Y, Zhang Z, Zhou G, Yang S, et al. Navigating chimeric antigen receptor-engineered natural killer cells as drug carriers via three-dimensional mapping of the tumor microenvironment. J Controlled Release. 2023;362:524\u201335.","journal-title":"J Controlled Release"},{"issue":"3","key":"2222_CR87","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nnano.2015.292","volume":"11","author":"PH Lizotte","year":"2016","unstructured":"Lizotte PH, Wen AM, Sheen MR, Fields J, Rojanasopondist P, Steinmetz NF, et al. In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer. Nat Nanotechnol. 2016;11(3):295\u2013303.","journal-title":"Nat Nanotechnol"},{"issue":"1","key":"2222_CR88","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12951-023-02259-6","volume":"22","author":"Z Chen","year":"2024","unstructured":"Chen Z, Xiong M, Tian J, Song D, Duan S, Zhang L. Encapsulation and assessment of therapeutic cargo in engineered exosomes: a systematic review. J Nanobiotechnol. 2024;22(1):18.","journal-title":"J Nanobiotechnol"},{"key":"2222_CR89","doi-asserted-by":"publisher","first-page":"103331","DOI":"10.1016\/j.cis.2024.103331","volume":"335","author":"M Aalhate","year":"2025","unstructured":"Aalhate M, Mahajan S, Dhuri A, Singh PK. Biohybrid nano-platforms manifesting effective cancer therapy: Fabrication, characterization, challenges and clinical perspective. Adv Colloid Interface Sci. 2025;335:103331.","journal-title":"Adv Colloid Interface Sci"},{"issue":"1","key":"2222_CR90","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-022-00699-x","volume":"20","author":"RH Fang","year":"2023","unstructured":"Fang RH, Gao W, Zhang L. Targeting drugs to tumours using cell membrane-coated nanoparticles. Nat Reviews Clin Oncol. 2023;20(1):33\u201348.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"4","key":"2222_CR91","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1021\/nl500618u","volume":"14","author":"RH Fang","year":"2014","unstructured":"Fang RH, Hu CM, Luk BT, Gao W, Copp JA, Tai Y, et al. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett. 2014;14(4):2181\u20138.","journal-title":"Nano Lett"},{"issue":"4","key":"2222_CR92","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41375-021-01432-w","volume":"36","author":"DT Johnson","year":"2022","unstructured":"Johnson DT, Zhou J, Kroll AV, Fang RH, Yan M, Xiao C, et al. Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy. Leukemia. 2022;36(4):994\u20131005.","journal-title":"Leukemia"},{"issue":"3","key":"2222_CR93","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1517\/17425247.2015.966684","volume":"12","author":"MJ Mitchell","year":"2015","unstructured":"Mitchell MJ, King MR. Leukocytes as carriers for targeted cancer drug delivery. Expert Opin Drug Deliv. 2015;12(3):375\u201392.","journal-title":"Expert Opin Drug Deliv"},{"issue":"3","key":"2222_CR94","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1073\/pnas.1316312111","volume":"111","author":"MJ Mitchell","year":"2014","unstructured":"Mitchell MJ, Wayne E, Rana K, Schaffer CB, King MR. TRAIL-coated leukocytes that kill cancer cells in the circulation. Proc Natl Acad Sci U S A. 2014;111(3):930\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2222_CR95","doi-asserted-by":"publisher","first-page":"21933","DOI":"10.1038\/srep21933","volume":"6","author":"YT Sato","year":"2016","unstructured":"Sato YT, Umezaki K, Sawada S, Mukai S-a, Sasaki Y, Harada N, et al. Engineering hybrid exosomes by membrane fusion with liposomes. Sci Rep. 2016;6(1):21933.","journal-title":"Sci Rep"},{"key":"2222_CR96","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.actbio.2019.05.054","volume":"94","author":"S Rayamajhi","year":"2019","unstructured":"Rayamajhi S, Nguyen TDT, Marasini R, Aryal S. Macrophage-derived exosome-mimetic hybrid vesicles for tumor targeted drug delivery. Acta Biomater. 2019;94:482\u201394.","journal-title":"Acta Biomater"},{"key":"2222_CR97","doi-asserted-by":"publisher","first-page":"216107","DOI":"10.1016\/j.canlet.2023.216107","volume":"558","author":"C Ducrot","year":"2023","unstructured":"Ducrot C, Loiseau S, Wong C, Madec E, Volatron J, Piffoux M. Hybrid extracellular vesicles for drug delivery. Cancer Lett. 2023;558:216107.","journal-title":"Cancer Lett"},{"issue":"33","key":"2222_CR98","doi-asserted-by":"publisher","first-page":"e2400049","DOI":"10.1002\/advs.202400049","volume":"11","author":"Z Luo","year":"2024","unstructured":"Luo Z, Cheng X, Feng B, Fan D, Liu X, Xie R, et al. Engineering Versatile Bacteria-Derived Outer Membrane Vesicles: An Adaptable Platform for Advancing Cancer Immunotherapy. Adv Sci (Weinh). 2024;11(33):e2400049.","journal-title":"Adv Sci (Weinh)"},{"issue":"37","key":"2222_CR99","doi-asserted-by":"publisher","first-page":"41138","DOI":"10.1021\/acsami.0c13169","volume":"12","author":"D Wang","year":"2020","unstructured":"Wang D, Liu C, You S, Zhang K, Li M, Cao Y, et al. Bacterial Vesicle-Cancer Cell Hybrid Membrane-Coated Nanoparticles for Tumor Specific Immune Activation and Photothermal Therapy. ACS Appl Mater Interfaces. 2020;12(37):41138\u201347.","journal-title":"ACS Appl Mater Interfaces"},{"key":"2222_CR100","doi-asserted-by":"publisher","first-page":"216848","DOI":"10.1016\/j.ccr.2025.216848","volume":"542","author":"S Lee","year":"2025","unstructured":"Lee S, Lee J, Park M, Kim J, Byun H, Kim J, et al. Inorganic nanoparticle-based cancer immunotheranostics. Coord Chem Rev. 2025;542:216848. https:\/\/doi.org\/10.1016\/j.ccr.2025.216848","journal-title":"Coord Chem Rev"},{"issue":"2","key":"2222_CR101","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1021\/acsnano.1c10565","volume":"16","author":"R Wang","year":"2022","unstructured":"Wang R, Kim KH, Yoo J, Li X, Kwon N, Jeon YH, et al. A Nanostructured Phthalocyanine\/Albumin Supramolecular Assembly for Fluorescence Turn-On Imaging and Photodynamic Immunotherapy. ACS Nano. 2022;16(2):3045\u201358.","journal-title":"ACS Nano"},{"issue":"1","key":"2222_CR102","doi-asserted-by":"publisher","first-page":"8696","DOI":"10.1038\/s41467-025-63718-2","volume":"16","author":"VS Kalluri","year":"2025","unstructured":"Kalluri VS, Smaglo BG, Mahadevan KK, Kirtley ML, McAndrews KM, Mendt M, et al. Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates. Nat Commun. 2025;16(1):8696.","journal-title":"Nat Commun"},{"issue":"7659","key":"2222_CR103","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature22341","volume":"546","author":"S Kamerkar","year":"2017","unstructured":"Kamerkar S, LeBleu VS, Sugimoto H, Yang S, Ruivo CF, Melo SA, et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 2017;546(7659):498\u2013503.","journal-title":"Nature"},{"issue":"1","key":"2222_CR104","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1479-5876-3-9","volume":"3","author":"MA Morse","year":"2005","unstructured":"Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM, et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med. 2005;3(1):9.","journal-title":"J Transl Med"},{"issue":"4","key":"2222_CR105","doi-asserted-by":"publisher","first-page":"e1071008","DOI":"10.1080\/2162402X.2015.1071008","volume":"5","author":"B Besse","year":"2016","unstructured":"Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology. 2016;5(4):e1071008.","journal-title":"Oncoimmunology"},{"issue":"10","key":"2222_CR106","first-page":"2497","volume":"13","author":"R Dhar","year":"2025","unstructured":"Dhar R, Sonar S, Das A, Tajul Akmal NAS, Hawa Jasni A, Rmt Balasubramaniam V, et al. Dendritic Cell-Derived Exosomes: Next Generation Cancer Immunotherapy Biomedicines. 2025;13(10):2497.","journal-title":"Dendritic Cell-Derived Exosomes: Next Generation Cancer Immunotherapy Biomedicines"},{"issue":"16","key":"2222_CR107","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1158\/1078-0432.CCR-25-4643","volume":"32","author":"RF Sweis","year":"2026","unstructured":"Sweis RF, Long GV, Daud A, Stemmer SM, Jimeno A, Perets R, et al. Lipid Nanoparticle\u2013Encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36\u03b3 plus Durvalumab Induces an Immunostimulatory Effect within the Tumor Microenvironment in Patients with Advanced Solid Tumors. Clin Cancer Res. 2026;32(16):3493\u20133505. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-4643","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2222_CR108","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1158\/2159-8290.CD-21-0425","volume":"11","author":"A Ribas","year":"2021","unstructured":"Ribas A, Medina T, Kirkwood JM, Zakharia Y, Gonzalez R, Davar D, et al. Overcoming PD-1 blockade resistance with CpG-A toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma. Cancer Discov. 2021;11(12):2998\u20133007.","journal-title":"Cancer Discov"},{"issue":"1","key":"2222_CR109","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/s41467-022-29121-x","volume":"13","author":"J Kim","year":"2022","unstructured":"Kim J, Francis DM, Sestito LF, Archer PA, Manspeaker MP, O\u2019Melia MJ, et al. Thermosensitive hydrogel releasing nitric oxide donor and anti-CTLA-4 micelles for anti-tumor immunotherapy. Nat Commun. 2022;13(1):1479.","journal-title":"Nat Commun"},{"issue":"10","key":"2222_CR110","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1021\/bm501166j","volume":"15","author":"Y Liu","year":"2014","unstructured":"Liu Y, Xiao L, Joo K-I, Hu B, Fang J, Wang P. In situ modulation of dendritic cells by injectable thermosensitive hydrogels for cancer vaccines in mice. Biomacromolecules. 2014;15(10):3836.","journal-title":"Biomacromolecules"},{"issue":"36","key":"2222_CR111","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1002\/adfm.201203859","volume":"23","author":"OA Ali","year":"2013","unstructured":"Ali OA, Tayalia P, Shvartsman D, Lewin S, Mooney DJ. Inflammatory cytokines presented from polymer matrices differentially generate and activate DCs in situ. Adv Funct Mater. 2013;23(36):4621\u20138.","journal-title":"Adv Funct Mater"},{"issue":"1","key":"2222_CR112","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1186\/s40001-025-03003-6","volume":"30","author":"S Zafar","year":"2025","unstructured":"Zafar S, Hafeez A, Shah H, Mutiullah I, Ali A, Khan K, et al. Emerging biomarkers for early cancer detection and diagnosis: challenges, innovations, and clinical perspectives. Eur J Med Res. 2025;30(1):760.","journal-title":"Eur J Med Res"},{"issue":"Suppl 9","key":"2222_CR113","doi-asserted-by":"publisher","first-page":"S1406","DOI":"10.21037\/tcr.2017.10.32","volume":"6","author":"TL Whiteside","year":"2017","unstructured":"Whiteside TL. Therapeutic targeting of oncogenic KRAS in pancreatic cancer by engineered exosomes. Transl Cancer Res. 2017;6(Suppl 9):S1406\u20138.","journal-title":"Transl Cancer Res"},{"key":"2222_CR114","doi-asserted-by":"publisher","first-page":"13007","DOI":"10.2147\/IJN.S548006","volume":"20","author":"Z Huang","year":"2025","unstructured":"Huang Z, Cheng J, Deng Z, Liu C, Huang T, Lin W. Extracellular Vesicle-Based Therapeutic Cargo Delivery for Cancer Therapy. Int J Nanomed. 2025;20:13007\u201337.","journal-title":"Int J Nanomed"},{"issue":"4","key":"2222_CR115","doi-asserted-by":"publisher","first-page":"EMMM202013243","DOI":"10.15252\/emmm.202013243","volume":"13","author":"SM Hammond","year":"2021","unstructured":"Hammond SM, Aartsma-Rus A, Alves S, Borgos SE, Buijsen RAM, Collin RWJ, et al. Delivery of oligonucleotide\u2010based therapeutics: challenges and opportunities. EMBO Mol Med. 2021;13(4):EMMM202013243.","journal-title":"EMBO Mol Med"},{"key":"2222_CR116","doi-asserted-by":"publisher","unstructured":"Wang X, Wang J, Wang Q, Ding G, Huang Y, Feng Y. Rewiring tumor cytokine networks to enhance immune checkpoint blockade: mechanisms, engineering, and clinical translation. J Exp Clin Cancer Res. 2026;45(1):65 https:\/\/doi.org\/10.1186\/s13046-026-03656-z","DOI":"10.1186\/s13046-026-03656-z"},{"issue":"5","key":"2222_CR117","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","volume":"25","author":"M Roerden","year":"2025","unstructured":"Roerden M, Spranger S. Cancer immune evasion, immunoediting and intratumour heterogeneity. Nat Rev Immunol. 2025;25(5):353\u201369.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2222_CR118","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12943-024-02214-5","volume":"24","author":"M Wang","year":"2025","unstructured":"Wang M, Yu F, Zhang Y. Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges. Mol Cancer. 2025;24(1):26.","journal-title":"Mol Cancer"},{"issue":"1","key":"2222_CR119","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s12672-025-04361-7","volume":"17","author":"H Saman","year":"2026","unstructured":"Saman H, Makni-Maalej K, El-Ella DMA, Al-Tamimi MY, AbuHaweeleh MN, Abuhayeh N, et al. Immune checkpoint blockade in cancer: current insights and future horizons. Discov Oncol. 2026;17(1):209.","journal-title":"Discov Oncol"},{"issue":"15","key":"2222_CR120","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1039\/C9TB00089E","volume":"7","author":"Q Lu","year":"2019","unstructured":"Lu Q, Qi S, Li P, Yang L, Yang S, Wang Y, et al. Photothermally activatable PDA immune nanomedicine combined with PD-L1 checkpoint blockade for antimetastatic cancer photoimmunotherapy. J Mater Chem B. 2019;7(15):2499\u2013511.","journal-title":"J Mater Chem B"},{"issue":"4","key":"2222_CR121","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41571-019-0308-z","volume":"17","author":"JD Martin","year":"2020","unstructured":"Martin JD, Cabral H, Stylianopoulos T, Jain RK. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. Nat Reviews Clin Oncol. 2020;17(4):251\u201366.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"11","key":"2222_CR122","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1038\/s41401-022-00910-w","volume":"43","author":"J-h Li","year":"2022","unstructured":"Li J-h, Huang L-j, Zhou H-l, Shan Y-m, Chen F-m, Lehto V-P, et al. Engineered nanomedicines block the PD-1\/PD-L1 axis for potentiated cancer immunotherapy. Acta Pharmacol Sin. 2022;43(11):2749\u201358.","journal-title":"Acta Pharmacol Sin"},{"issue":"10","key":"2222_CR123","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.7150\/thno.38069","volume":"10","author":"P Mi","year":"2020","unstructured":"Mi P. Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics. Theranostics. 2020;10(10):4557\u201388.","journal-title":"Theranostics"},{"key":"2222_CR124","doi-asserted-by":"publisher","unstructured":"Camorani S, Tortorella S, Agnello L, Spanu C, d\u2019Argenio A, Nilo R et al. Aptamer-Functionalized Nanoparticles Mediate PD-L1 siRNA Delivery for Effective Gene Silencing in Triple-Negative Breast Cancer Cells. Pharmaceutics. 2022;14(10):222514(10). https:\/\/doi.org\/10.3390\/pharmaceutics14102225","DOI":"10.3390\/pharmaceutics14102225"},{"issue":"Pt 3","key":"2222_CR125","doi-asserted-by":"publisher","first-page":"143994","DOI":"10.1016\/j.ijbiomac.2025.143994","volume":"311","author":"G Sristi, Gupta","year":"2025","unstructured":"Sristi, Gupta G, Abourehab MAS, Sahebkar A, Kesharwani P. Recent advances in PD-L1 siRNA nanocarriers for cancer therapy. Int J Biol Macromol. 2025;311(Pt 3):143994.","journal-title":"Int J Biol Macromol"},{"key":"2222_CR126","first-page":"101166","volume":"47","author":"DE Uti","year":"2026","unstructured":"Uti DE, Alum EU, Ugwu OP-C. Nanovaccines in cancer immunoprevention and immunotherapy: Current insights and future directions. Cancer Treat Res Commun. 2026;47:101166.","journal-title":"Cancer Treat Res Commun"},{"issue":"5","key":"2222_CR127","doi-asserted-by":"publisher","first-page":"e22244","DOI":"10.1002\/ddr.22244","volume":"85","author":"Z Jahanafrooz","year":"2024","unstructured":"Jahanafrooz Z, Oroojalian F, Mokhtarzadeh A, Rahdar A, D\u00edez-Pascual AM, Nanovaccines. Immunogenic tumor antigens, targeted delivery, and combination therapy to enhance cancer immunotherapy. Drug Dev Res. 2024;85(5):e22244.","journal-title":"Drug Dev Res"},{"key":"2222_CR128","doi-asserted-by":"publisher","first-page":"119795","DOI":"10.1016\/j.biomaterials.2020.119795","volume":"235","author":"S Zhou","year":"2020","unstructured":"Zhou S, Huang Y, Chen Y, Liu S, Xu M, Jiang T, et al. Engineering ApoE3-incorporated biomimetic nanoparticle for efficient vaccine delivery to dendritic cells via macropinocytosis to enhance cancer immunotherapy. Biomaterials. 2020;235:119795.","journal-title":"Biomaterials"},{"key":"2222_CR129","doi-asserted-by":"publisher","first-page":"102481","DOI":"10.1016\/j.nantod.2024.102481","volume":"59","author":"W Li","year":"2024","unstructured":"Li W, Zhang Q-L, Ma X-Y, Zeng X, Zhang X-Z. A multi-adjuvant nanovaccine platform based on targeted delivery of specific antigens for cancer immunotherapy. Nano Today. 2024;59:102481.","journal-title":"Nano Today"},{"issue":"35","key":"2222_CR130","doi-asserted-by":"publisher","first-page":"2401631","DOI":"10.1002\/smll.202401631","volume":"20","author":"N Desai","year":"2024","unstructured":"Desai N, Chavda V, Singh TRR, Thorat ND, Vora LK. Cancer Nanovaccines: Nanomaterials and Clinical Perspectives. Small. 2024;20(35):2401631.","journal-title":"Small"},{"issue":"7","key":"2222_CR131","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/nnano.2017.52","volume":"12","author":"M Luo","year":"2017","unstructured":"Luo M, Wang H, Wang Z, Cai H, Lu Z, Li Y, et al. A STING-activating nanovaccine for cancer immunotherapy. Nat Nanotechnol. 2017;12(7):648\u201354.","journal-title":"Nat Nanotechnol"},{"key":"2222_CR132","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jconrel.2022.03.020","volume":"345","author":"CS Carson","year":"2022","unstructured":"Carson CS, Becker KW, Garland KM, Pagendarm HM, Stone PT, Arora K, et al. A nanovaccine for enhancing cellular immunity via cytosolic co-delivery of antigen and polyIC RNA. J Controlled Release. 2022;345:354\u201370.","journal-title":"J Controlled Release"},{"key":"2222_CR133","doi-asserted-by":"publisher","first-page":"1218082","DOI":"10.3389\/fimmu.2023.1218082","volume":"14","author":"Y Fu","year":"2023","unstructured":"FuY, Tang R, Zhao X. Engineering cytokines for cancer immunotherapy: a systematic review. Front Immunol. 2023;14:1218082. https:\/\/doi.org\/10.3389\/fimmu.2023.1218082","journal-title":"Front Immunol"},{"key":"2222_CR134","doi-asserted-by":"publisher","unstructured":"Rokade S, Damani AM, Oft M, Emmerich J. IL-2 based cancer immunotherapies: an evolving paradigm. Front Immunol. 2024; 15, p.1433989. https:\/\/doi.org\/10.3389\/fimmu.2024.1433989","DOI":"10.3389\/fimmu.2024.1433989"},{"key":"2222_CR135","doi-asserted-by":"publisher","first-page":"575597","DOI":"10.3389\/fimmu.2020.575597","volume":"11","author":"KG Nguyen","year":"2020","unstructured":"Nguyen KG, Vrabel MR, Mantooth SM, Hopkins JJ, Wagner ES, Gabaldon TA, et al. Localized Interleukin-12 for Cancer Immunotherapy. Front Immunol. 2020;11:575597.","journal-title":"Front Immunol"},{"key":"2222_CR136","doi-asserted-by":"publisher","first-page":"952231","DOI":"10.3389\/fimmu.2022.952231","volume":"13","author":"Z Jia","year":"2022","unstructured":"Jia Z, Ragoonanan D, Mahadeo KM, Gill J, Gorlick R, Shpal E, et al. IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines. Front Immunol. 2022;13:952231.","journal-title":"Front Immunol"},{"issue":"10","key":"2222_CR137","doi-asserted-by":"publisher","first-page":"11548","DOI":"10.3390\/cimb46100686","volume":"46","author":"C Dong","year":"2024","unstructured":"Dong C, Tan D, Sun H, Li Z, Zhang L, Zheng Y, et al. Interleukin-12 Delivery Strategies and Advances in Tumor Immunotherapy. Curr Issues Mol Biol. 2024;46(10):11548\u201379.","journal-title":"Curr Issues Mol Biol"},{"issue":"12","key":"2222_CR138","doi-asserted-by":"publisher","first-page":"4775","DOI":"10.1007\/s13346-025-01896-8","volume":"15","author":"MJ Silveira","year":"2025","unstructured":"Silveira MJ, Martins C, Cardoso AP, Ankone MJK, Blyth RRR, Oliveira MJ, et al. Immunostimulatory effects of IL-12 targeted pH-responsive nanoparticles in macrophage-enriched 3D immuno-spheroids in vitro model. Drug Delivery Translational Res. 2025;15(12):4775\u201394.","journal-title":"Drug Delivery Translational Res"},{"issue":"4","key":"2222_CR139","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1039\/C8BM01556B","volume":"7","author":"YQ Xie","year":"2019","unstructured":"Xie YQ, Arik H, Wei L, Zheng Y, Suh H, Irvine DJ, et al. Redox-responsive interleukin-2 nanogel specifically and safely promotes the proliferation and memory precursor differentiation of tumor-reactive T-cells. Biomater Sci. 2019;7(4):1345\u201357.","journal-title":"Biomater Sci"},{"key":"2222_CR140","doi-asserted-by":"publisher","first-page":"118953","DOI":"10.1016\/j.biopha.2025.118953","volume":"194","author":"H Khorramdelazad","year":"2026","unstructured":"Khorramdelazad H, Pirsadeghi A, Amraei E, Amani A, Abbasnia M, Nematzade F, et al. Hydrogel-based delivery of cytokines in cancer immunotherapy: Latest evidence and therapeutic outcomes. Biomed Pharmacother. 2026;194:118953.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"2222_CR141","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s44222-023-00148-z","volume":"2","author":"N Eckman","year":"2024","unstructured":"Eckman N, Nejatfard A, Cavet R, Grosskopf AK, Appel EA. Biomaterials to enhance adoptive cell therapy. Nat Reviews Bioeng. 2024;2(5):408\u201324.","journal-title":"Nat Reviews Bioeng"},{"issue":"10","key":"2222_CR142","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.trecan.2025.08.009","volume":"11","author":"N Kwon","year":"2025","unstructured":"Kwon N, Chen YY. Overcoming solid-tumor barriers: armored CAR-T cell therapy. Trends Cancer. 2025;11(10):1019\u201329.","journal-title":"Trends Cancer"},{"key":"2222_CR143","doi-asserted-by":"publisher","first-page":"600659","DOI":"10.3389\/fimmu.2021.600659","volume":"12","author":"PB Balakrishnan","year":"2021","unstructured":"Balakrishnan PB, Sweeney EE. Nanoparticles for Enhanced Adoptive T Cell Therapies and Future Perspectives for CNS Tumors. Front Immunol. 2021;12:600659.","journal-title":"Front Immunol"},{"issue":"6753","key":"2222_CR144","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"TL Hunter","year":"2025","unstructured":"Hunter TL, Bao Y, Zhang Y, Matsuda D, Riener R, Wang A, et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science. 2025;388(6753):1311\u20137.","journal-title":"Science"},{"issue":"8","key":"2222_CR145","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nbt.4181","volume":"36","author":"L Tang","year":"2018","unstructured":"Tang L, Zheng Y, Melo MB, Mabardi L, Casta\u00f1o AP, Xie YQ, et al. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat Biotechnol. 2018;36(8):707\u201316.","journal-title":"Nat Biotechnol"},{"key":"2222_CR146","doi-asserted-by":"publisher","first-page":"114083","DOI":"10.1016\/j.addr.2021.114083","volume":"181","author":"MA Younis","year":"2022","unstructured":"Younis MA, Tawfeek HM, Abdellatif AAH, Abdel-Aleem JA, Harashima H. Clinical translation of nanomedicines: Challenges, opportunities, and keys. Adv Drug Deliv Rev. 2022;181:114083.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"2222_CR147","doi-asserted-by":"publisher","first-page":"107508","DOI":"10.1016\/j.cclet.2022.05.022","volume":"34","author":"T Wang","year":"2023","unstructured":"Wang T, Fu Y, Sun S, Huang C, Yi Y, Wang J, et al. Exosome-based drug delivery systems in cancer therapy. Chin Chem Lett. 2023;34(2):107508.","journal-title":"Chin Chem Lett"},{"key":"2222_CR148","doi-asserted-by":"publisher","first-page":"100032","DOI":"10.1016\/j.vesic.2023.100032","volume":"3","author":"V Sharma","year":"2024","unstructured":"Sharma V, Mukhopadhyay CD. Exosome as drug delivery system: Current advancements. Extracell Vesicle. 2024;3:100032.","journal-title":"Extracell Vesicle"},{"issue":"1","key":"2222_CR149","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12943-022-01515-x","volume":"21","author":"L Huang","year":"2022","unstructured":"Huang L, Rong Y, Tang X, Yi K, Qi P, Hou J, et al. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer. Mol Cancer. 2022;21(1):45.","journal-title":"Mol Cancer"},{"key":"2222_CR150","doi-asserted-by":"publisher","first-page":"5753","DOI":"10.2147\/ott.s173110","volume":"11","author":"H Gomari","year":"2018","unstructured":"Gomari H, Forouzandeh Moghadam M, Soleimani M. Targeted cancer therapy using engineered exosome as a natural drug delivery vehicle. OncoTargets Therapy. 2018;11:5753\u201362. https:\/\/doi.org\/10.2147\/ott.s173110","journal-title":"OncoTargets Therapy"},{"key":"2222_CR151","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.jconrel.2022.11.053","volume":"353","author":"J Li","year":"2023","unstructured":"Li J, Li J, Peng Y, Du Y, Yang Z, Qi X. Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies. J Controlled Release. 2023;353:423\u201333.","journal-title":"J Controlled Release"},{"issue":"1","key":"2222_CR152","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12943-022-01557-1","volume":"21","author":"D-D Shen","year":"2022","unstructured":"Shen D-D, Pang J-R, Bi Y-P, Zhao L-F, Li Y-R, Zhao L-J, et al. LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer. Mol Cancer. 2022;21(1):75.","journal-title":"Mol Cancer"},{"issue":"1","key":"2222_CR153","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41467-022-35710-7","volume":"14","author":"W Lin","year":"2023","unstructured":"Lin W, Chen L, Zhang H, Qiu X, Huang Q, Wan F, et al. Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation. Nat Commun. 2023;14(1):265.","journal-title":"Nat Commun"},{"key":"2222_CR154","doi-asserted-by":"publisher","first-page":"120546","DOI":"10.1016\/j.biomaterials.2020.120546","volume":"268","author":"W Zhou","year":"2021","unstructured":"Zhou W, Zhou Y, Chen X, Ning T, Chen H, Guo Q, et al. Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment. Biomaterials. 2021;268:120546.","journal-title":"Biomaterials"},{"issue":"7","key":"2222_CR155","doi-asserted-by":"publisher","first-page":"eabj7002","DOI":"10.1126\/sciadv.abj7002","volume":"8","author":"S Kamerkar","year":"2022","unstructured":"Kamerkar S, Leng C, Burenkova O, Jang SC, McCoy C, Zhang K, et al. Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity. Sci Adv. 2022;8(7):eabj7002.","journal-title":"Sci Adv"},{"issue":"17","key":"2222_CR156","doi-asserted-by":"publisher","first-page":"16770","DOI":"10.1021\/acsnano.3c03456","volume":"17","author":"T Zhu","year":"2023","unstructured":"Zhu T, Chen Z, Jiang G, Huang X. Sequential targeting hybrid nanovesicles composed of chimeric antigen receptor T-cell-derived exosomes and liposomes for enhanced cancer immunochemotherapy. ACS Nano. 2023;17(17):16770\u201386.","journal-title":"ACS Nano"},{"issue":"7","key":"2222_CR157","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1016\/j.biomaterials.2013.11.083","volume":"35","author":"Y Tian","year":"2014","unstructured":"Tian Y, Li S, Song J, Ji T, Zhu M, Anderson GJ, et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials. 2014;35(7):2383\u201390.","journal-title":"Biomaterials"},{"issue":"7","key":"2222_CR158","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1093\/nar\/gkz097","volume":"47","author":"J Alles","year":"2019","unstructured":"Alles J, Fehlmann T, Fischer U, Backes C, Galata V, Minet M, et al. An estimate of the total number of true human miRNAs. Nucleic Acids Res. 2019;47(7):3353\u201364.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"2222_CR159","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1158\/1078-0432.CCR-18-1981","volume":"25","author":"M Boeri","year":"2019","unstructured":"Boeri M, Milione M, Proto C, Signorelli D, Lo Russo G, Galeone C, et al. Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study. Clin Cancer Res. 2019;25(7):2166\u201373.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2222_CR160","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1134\/S0026893320060072","volume":"54","author":"NE Kushlinskii","year":"2020","unstructured":"Kushlinskii NE, Loginov VI, Utkin DO, Filippova EA, Burdennyy AM, Korotkova EA, et al. [Novel miRNAs as Potential Regulators of PD-1\/PD-L1 Immune Checkpoint, and Prognostic Value of MIR9-1 and MIR124-2 Methylation in Ovarian Cancer]. Mol Biol (Mosk). 2020;54(6):990\u20136.","journal-title":"Mol Biol (Mosk)"},{"issue":"1","key":"2222_CR161","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12935-024-03293-6","volume":"24","author":"A Zabeti Touchaei","year":"2024","unstructured":"Zabeti Touchaei A, Vahidi S. MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1\/PD-L1 and CTLA-4 pathways. Cancer Cell Int. 2024;24(1):102.","journal-title":"Cancer Cell Int"},{"issue":"13","key":"2222_CR162","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.3390\/cancers17132172","volume":"17","author":"E Zare","year":"2025","unstructured":"Zare E, Yaghoubi SM, Khoshnazar M, Jafari Dargahlou S, Machhar JS, Zheng Z, et al. MicroRNAs in Cancer Immunology: Master Regulators of the Tumor Microenvironment and Immune Evasion, with Therapeutic Potential. Cancers. 2025;17(13):2172.","journal-title":"Cancers"},{"issue":"1","key":"2222_CR163","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00253-025-13620-0","volume":"109","author":"Z Wang","year":"2025","unstructured":"Wang Z, Peng Y, Zhou H, Zhang M, Ju D, Chen Z. MiRNA-based drugs: challenges and delivery strategies. Appl Microbiol Biotechnol. 2025;109(1):247.","journal-title":"Appl Microbiol Biotechnol"},{"key":"2222_CR164","doi-asserted-by":"publisher","first-page":"619939","DOI":"10.3389\/fmed.2021.619939","volume":"8","author":"R Rezaei","year":"2021","unstructured":"Rezaei R, Baghaei K, Hashemi SM, Zali MR, Ghanbarian H, Amani D. Tumor-Derived Exosomes Enriched by miRNA-124 Promote Anti-tumor Immune Response in CT-26 Tumor-Bearing Mice. Front Med (Lausanne). 2021;8:619939.","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"2222_CR165","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.3390\/cells12101416","volume":"12","author":"H Zeng","year":"2023","unstructured":"Zeng H, Guo S, Ren X, Wu Z, Liu S, Yao X. Current Strategies for Exosome Cargo Loading and Targeting Delivery. Cells. 2023;12(10):1416.","journal-title":"Cells"},{"key":"2222_CR166","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1038\/ncomms3980","volume":"4","author":"C Villarroya-Beltri","year":"2013","unstructured":"Villarroya-Beltri C, Guti\u00e9rrez-V\u00e1zquez C, S\u00e1nchez-Cabo F, P\u00e9rez-Hern\u00e1ndez D, V\u00e1zquez J, Martin-Cofreces N, et al. Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. Nat Commun. 2013;4:2980.","journal-title":"Nat Commun"},{"issue":"4","key":"2222_CR167","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/s12276-024-01201-6","volume":"56","author":"HI Kim","year":"2024","unstructured":"Kim HI, Park J, Zhu Y, Wang X, Han Y, Zhang D. Recent advances in extracellular vesicles for therapeutic cargo delivery. Exp Mol Med. 2024;56(4):836\u201349.","journal-title":"Exp Mol Med"},{"issue":"8","key":"2222_CR168","doi-asserted-by":"publisher","first-page":"e70003","DOI":"10.1002\/jex2.70003","volume":"3","author":"NM Lowe","year":"2024","unstructured":"Lowe NM, Mizenko RR, Nguyen BB, Chiu KL, Arun V, Panitch A, et al. Orthogonal analysis reveals inconsistencies in cargo loading of extracellular vesicles. J Extracell Biol. 2024;3(8):e70003.","journal-title":"J Extracell Biol"},{"key":"2222_CR169","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.addr.2021.04.012","volume":"173","author":"S Rankin-Turner","year":"2021","unstructured":"Rankin-Turner S, Vader P, O\u2019Driscoll L, Giebel B, Heaney LM, Davies OG. A call for the standardised reporting of factors affecting the exogenous loading of extracellular vesicles with therapeutic cargos. Adv Drug Deliv Rev. 2021;173:479\u201391.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"2222_CR170","doi-asserted-by":"publisher","first-page":"102870","DOI":"10.1016\/j.omtn.2026.102870","volume":"37","author":"X Zhang","year":"2026","unstructured":"Zhang X, Liu X, Zhou Q, Yao K. Extracellular vesicle-based delivery systems for nucleic acid therapeutics. Mol Ther Nucleic Acids. 2026;37(2):102870.","journal-title":"Mol Ther Nucleic Acids"},{"key":"2222_CR171","doi-asserted-by":"publisher","first-page":"113972","DOI":"10.1016\/j.addr.2021.113972","volume":"178","author":"M Piffoux","year":"2021","unstructured":"Piffoux M, Volatron J, Cherukula K, Aubertin K, Wilhelm C, Silva AKA, et al. Engineering and loading therapeutic extracellular vesicles for clinical translation: A data reporting frame for comparability. Adv Drug Deliv Rev. 2021;178:113972.","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"2222_CR172","doi-asserted-by":"publisher","first-page":"e2101557","DOI":"10.1002\/adhm.202101557","volume":"11","author":"BZ Wang","year":"2022","unstructured":"Wang BZ, Luo LJ, Vunjak-Novakovic G. RNA and Protein Delivery by Cell-Secreted and Bioengineered Extracellular Vesicles. Adv Healthc Mater. 2022;11(5):e2101557.","journal-title":"Adv Healthc Mater"},{"issue":"9","key":"2222_CR173","doi-asserted-by":"publisher","first-page":"e12343","DOI":"10.1002\/jev2.12343","volume":"12","author":"JA Whitley","year":"2023","unstructured":"Whitley JA, Cai H. Engineering extracellular vesicles to deliver CRISPR ribonucleoprotein for gene editing. J Extracell Vesicles. 2023;12(9):e12343.","journal-title":"J Extracell Vesicles"},{"issue":"1","key":"2222_CR174","doi-asserted-by":"publisher","first-page":"6297","DOI":"10.1038\/s41598-022-10336-3","volume":"12","author":"M Drobna-\u015aledzi\u0144ska","year":"2022","unstructured":"Drobna-\u015aledzi\u0144ska M, Ma\u0107kowska-Ma\u015blak N, Jaksik R, D\u0105bek P, Witt M, Dawidowska M. CRISPRi for specific inhibition of miRNA clusters and miRNAs with high sequence homology. Sci Rep. 2022;12(1):6297.","journal-title":"Sci Rep"},{"issue":"12","key":"2222_CR175","doi-asserted-by":"publisher","first-page":"3840","DOI":"10.1016\/j.biomaterials.2014.01.019","volume":"35","author":"L Li","year":"2014","unstructured":"Li L, Hou J, Liu X, Guo Y, Wu Y, Zhang L, et al. Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas. Biomaterials. 2014;35(12):3840\u201350.","journal-title":"Biomaterials"},{"issue":"24","key":"2222_CR176","doi-asserted-by":"publisher","first-page":"11457","DOI":"10.1039\/D4NR00207E","volume":"16","author":"R Chowdhury","year":"2024","unstructured":"Chowdhury R, Eslami S, Pham CV, Rai A, Lin J, Hou Y, et al. Role of aptamer technology in extracellular vesicle biology and therapeutic applications. Nanoscale. 2024;16(24):11457\u201379.","journal-title":"Nanoscale"},{"issue":"11","key":"2222_CR177","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/nrgastro.2017.113","volume":"14","author":"L Buscail","year":"2017","unstructured":"Buscail L. Pancreatic cancer: Exosomes for targeting KRAS in the treatment of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2017;14(11):636\u20138.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"2222_CR178","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nrc.2017.59","volume":"17","author":"CA Bradley","year":"2017","unstructured":"Bradley CA. Pancreatic cancer: iExosomes target the \u2018undruggable\u2019. Nat Rev Cancer. 2017;17(8):452\u20133.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"2222_CR179","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/s41551-017-0119-4","volume":"1","author":"SAA Kooijmans","year":"2017","unstructured":"Kooijmans SAA, Vader P, Schiffelers RM. Tumour-bound RNA-laden exosomes. Nat Biomed Eng. 2017;1(8):634\u20136.","journal-title":"Nat Biomed Eng"},{"key":"2222_CR180","doi-asserted-by":"publisher","first-page":"27066","DOI":"10.3402\/jev.v4.27066","volume":"4","author":"M Y\u00e1\u00f1ez-M\u00f3","year":"2015","unstructured":"Y\u00e1\u00f1ez-M\u00f3 M, Siljander PR, Andreu Z, Zavec AB, Borr\u00e0s FE, Buzas EI, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015;4:27066.","journal-title":"J Extracell Vesicles"},{"key":"2222_CR181","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jconrel.2020.07.043","volume":"327","author":"F Combes","year":"2020","unstructured":"Combes F, Meyer E, Sanders NN. Immune cells as tumor drug delivery vehicles. J Controlled Release. 2020;327:70\u201387.","journal-title":"J Controlled Release"},{"key":"2222_CR182","doi-asserted-by":"publisher","first-page":"114321","DOI":"10.1016\/j.addr.2022.114321","volume":"186","author":"Q Long","year":"2022","unstructured":"Long Q, Zheng P, Zheng X, Li W, Hua L, Yang Z, et al. Engineered bacterial membrane vesicles are promising carriers for vaccine design and tumor immunotherapy. Adv Drug Deliv Rev. 2022;186:114321.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"2222_CR183","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","volume":"28","author":"JL Shirley","year":"2020","unstructured":"Shirley JL, De Jong YP, Terhorst C, Herzog RW. Immune responses to viral gene therapy vectors. Mol Ther. 2020;28(3):709\u201322.","journal-title":"Mol Ther"},{"issue":"11","key":"2222_CR184","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1038\/s41401-022-00902-w","volume":"43","author":"A Mukherjee","year":"2022","unstructured":"Mukherjee A, Bisht B, Dutta S, Paul MK. Current advances in the use of exosomes, liposomes, and bioengineered hybrid nanovesicles in cancer detection and therapy. Acta Pharmacol Sin. 2022;43(11):2759\u201376.","journal-title":"Acta Pharmacol Sin"},{"issue":"4","key":"2222_CR185","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s13770-021-00361-0","volume":"18","author":"H Choi","year":"2021","unstructured":"Choi H, Choi Y, Yim HY, Mirzaaghasi A, Yoo J-K, Choi C. Biodistribution of exosomes and engineering strategies for targeted delivery of therapeutic exosomes. Tissue Eng regenerative Med. 2021;18(4):499\u2013511.","journal-title":"Tissue Eng regenerative Med"},{"issue":"33","key":"2222_CR186","doi-asserted-by":"publisher","first-page":"2403199","DOI":"10.1002\/adma.202403199","volume":"36","author":"Y Xia","year":"2024","unstructured":"Xia Y, Zhang J, Liu G, Wolfram J. Immunogenicity of extracellular vesicles. Adv Mater. 2024;36(33):2403199.","journal-title":"Adv Mater"},{"issue":"3","key":"2222_CR187","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s13346-022-01262-y","volume":"13","author":"DA Dri","year":"2023","unstructured":"Dri DA, Rinaldi F, Carafa M, Marianecci C. Nanomedicines and nanocarriers in clinical trials: surfing through regulatory requirements and physico-chemical critical quality attributes. Drug Delivery Translational Res. 2023;13(3):757\u201369.","journal-title":"Drug Delivery Translational Res"},{"key":"2222_CR188","unstructured":"Administration USFaD. Drug Products, Including Biological Products, that Contain Nanomaterials: Guidance for Industry. Silver Spring, MD: U.S. Food and Drug Administration; 2022. https:\/\/collections.nlm.nih.gov\/catalog\/nlm:nlmuid-9918452382006676-pdf"},{"issue":"1","key":"2222_CR189","doi-asserted-by":"publisher","first-page":"1535750","DOI":"10.1080\/20013078.2018.1535750","volume":"7","author":"C Th\u00e9ry","year":"2018","unstructured":"Th\u00e9ry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7(1):1535750.","journal-title":"J Extracell Vesicles"},{"key":"2222_CR190","doi-asserted-by":"publisher","first-page":"1655095","DOI":"10.3389\/fimmu.2025.1655095","volume":"16","author":"X Zhao","year":"2025","unstructured":"Zhao X, Zhao B, Sun Y, Liu A. CAR-exosomes derived from immune cells: an emerging nanoscale vanguard in overcoming tumor immunotherapy hurdles. Front Immunol. 2025;16:1655095.","journal-title":"Front Immunol"},{"issue":"15","key":"2222_CR191","doi-asserted-by":"publisher","first-page":"2103222","DOI":"10.1002\/advs.202103222","volume":"9","author":"JJ Lai","year":"2022","unstructured":"Lai JJ, Chau ZL, Chen SY, Hill JJ, Korpany KV, Liang NW, et al. Exosome processing and characterization approaches for research and technology development. Adv Sci. 2022;9(15):2103222.","journal-title":"Adv Sci"},{"issue":"2","key":"2222_CR192","doi-asserted-by":"publisher","first-page":"e12404","DOI":"10.1002\/jev2.12404","volume":"13","author":"JA Welsh","year":"2024","unstructured":"Welsh JA, Goberdhan DC, O\u2019Driscoll L, Buzas EI, Blenkiron C, Bussolati B, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell vesicles. 2024;13(2):e12404.","journal-title":"J Extracell vesicles"},{"issue":"1","key":"2222_CR193","doi-asserted-by":"publisher","first-page":"e12033","DOI":"10.1002\/jev2.12033","volume":"10","author":"VV Nguyen","year":"2020","unstructured":"Nguyen VV, Witwer KW, Verhaar MC, Strunk D, van Balkom BW. Functional assays to assess the therapeutic potential of extracellular vesicles. J Extracell Vesicles. 2020;10(1):e12033.","journal-title":"J Extracell Vesicles"},{"issue":"8","key":"2222_CR194","doi-asserted-by":"publisher","first-page":"e13904","DOI":"10.1111\/cts.13904","volume":"17","author":"CK Wang","year":"2024","unstructured":"Wang CK, Tsai TH, Lee CH. Regulation of exosomes as biologic medicines: Regulatory challenges faced in exosome development and manufacturing processes. Clin Transl Sci. 2024;17(8):e13904.","journal-title":"Clin Transl Sci"},{"issue":"1","key":"2222_CR195","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/pharmaceutics18010011","volume":"18","author":"AB Uzakova","year":"2025","unstructured":"Uzakova AB, Yergaliyeva EM, Yerlanuly A, Mukatayeva ZS. A systematic review of advanced drug delivery systems: engineering strategies, barrier penetration, and clinical progress (2016\u2013April 2025). Pharmaceutics. 2025;18(1):11.","journal-title":"Pharmaceutics"},{"issue":"14","key":"2222_CR196","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.3390\/ijms25147794","volume":"25","author":"KWA Lee","year":"2024","unstructured":"Lee KWA, Chan LKW, Hung LC, Phoebe LKW, Park Y, Yi K-H. Clinical applications of exosomes: a critical review. Int J Mol Sci. 2024;25(14):7794.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2222_CR197","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/pharmaceutics18010045","volume":"18","author":"LL Dieu","year":"2025","unstructured":"Dieu LL, Kazsoki A, Zelk\u00f3 R. Drug-loaded extracellular vesicle-based drug delivery: advances, loading strategies, therapeutic applications, and clinical challenges. Pharmaceutics. 2025;18(1):45.","journal-title":"Pharmaceutics"},{"issue":"15","key":"2222_CR198","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.3390\/cells14151136","volume":"14","author":"MA Rauf","year":"2025","unstructured":"Rauf MA, Rao A, Sivasoorian SS, Iyer AK. Nanotechnology-based delivery of CRISPR\/Cas9 for cancer treatment: a comprehensive review. Cells. 2025;14(15):1136.","journal-title":"Cells"},{"issue":"2","key":"2222_CR199","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/ddc4020019","volume":"4","author":"T Premchandani","year":"2025","unstructured":"Premchandani T, Tatode A, Taksande J, Umekar M, Qutub M, Hussain UM, et al. Engineered exosomes as smart drug carriers: overcoming biological barriers in CNS and cancer therapy. Drugs Drug Candidates. 2025;4(2):19.","journal-title":"Drugs Drug Candidates"},{"issue":"2","key":"2222_CR200","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discovery. 2021;20(2):101\u201324.","journal-title":"Nat Rev Drug Discovery"},{"issue":"3","key":"2222_CR201","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1089\/nat.2018.0721","volume":"28","author":"JA Kulkarni","year":"2018","unstructured":"Kulkarni JA, Cullis PR, Van Der Meel R. Lipid nanoparticles enabling gene therapies: from concepts to clinical utility. Nucleic acid Ther. 2018;28(3):146\u201357.","journal-title":"Nucleic acid Ther"},{"key":"2222_CR202","doi-asserted-by":"publisher","first-page":"1483454","DOI":"10.3389\/fonc.2024.1483454","volume":"14","author":"X Yin","year":"2024","unstructured":"Yin X, Song Y, Deng W, Blake N, Luo X, Meng J. Potential predictive biomarkers in antitumor immunotherapy: navigating the future of antitumor treatment and immune checkpoint inhibitor efficacy. Front Oncol. 2024;14:1483454.","journal-title":"Front Oncol"},{"issue":"7","key":"2222_CR203","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","volume":"24","author":"AM Holder","year":"2024","unstructured":"Holder AM, Dedeilia A, Sierra-Davidson K, Cohen S, Liu D, Parikh A, et al. Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nat Rev Cancer. 2024;24(7):498\u2013512.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2222_CR204","doi-asserted-by":"publisher","first-page":"e10143","DOI":"10.1002\/btm2.10143","volume":"4","author":"AC Anselmo","year":"2019","unstructured":"Anselmo AC, Mitragotri S. Nanoparticles in the clinic: An update. Bioeng translational Med. 2019;4(3):e10143.","journal-title":"Bioeng translational Med"},{"issue":"26","key":"2222_CR205","doi-asserted-by":"publisher","first-page":"2312169","DOI":"10.1002\/adma.202312169","volume":"36","author":"T Lammers","year":"2024","unstructured":"Lammers T. Nanomedicine tumor targeting. Adv Mater. 2024;36(26):2312169.","journal-title":"Adv Mater"},{"key":"2222_CR206","doi-asserted-by":"publisher","first-page":"1487627","DOI":"10.3389\/fbioe.2025.1487627","volume":"13","author":"Z Li","year":"2025","unstructured":"Li Z, Yan J, Li X, Chen H, Lin C, Zhang Y, et al. Advancements in extracellular vesicles biomanufacturing: a comprehensive overview of large-scale production and clinical research. Front Bioeng Biotechnol. 2025;13:1487627.","journal-title":"Front Bioeng Biotechnol"},{"key":"2222_CR207","doi-asserted-by":"publisher","first-page":"103045","DOI":"10.1016\/j.copbio.2023.103045","volume":"85","author":"F Tong","year":"2024","unstructured":"Tong F, Wang Y, Gao H. Progress and challenges in the translation of cancer nanomedicines. Curr Opin Biotechnol. 2024;85:103045.","journal-title":"Curr Opin Biotechnol"},{"key":"2222_CR208","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jconrel.2017.04.020","volume":"256","author":"C Zhang","year":"2017","unstructured":"Zhang C, Shi G, Zhang J, Song H, Niu J, Shi S, et al. Targeted antigen delivery to dendritic cell via functionalized alginate nanoparticles for cancer immunotherapy. J Control Release. 2017;256:170\u201381.","journal-title":"J Control Release"},{"key":"2222_CR209","unstructured":"Center MDAC. Exosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation 2026 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT03608631?cond=NCT03608631&viewType=Table&rank=1"},{"key":"2222_CR210","unstructured":"Gustave Roussy CC, Grand Paris. Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes (CSET 1437): National Library of Medicine; 2018 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT01159288?cond=NCT01159288&viewType=Table&rank=1"},{"key":"2222_CR211","unstructured":"Pharmaceuticals R. Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy 2025 [updated July 4, 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02680184?cond=NCT02680184&viewType=Table&rank=1"},{"key":"2222_CR212","unstructured":"University E. Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer 2025 [updated September 19, 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05445609?cond=NCT05445609&viewType=Table&rank=1"},{"key":"2222_CR213","unstructured":"Inc IB. A Study to Evaluate the Safety and Tolerability of ILB-202 2025 [ClinicalTrials.gov Identifier: NCT05843799]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05843799?cond=NCT05843799&viewType=Table&rank=1"},{"issue":"1","key":"2222_CR214","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1479-5876-3-10","volume":"3","author":"B Escudier","year":"2005","unstructured":"Escudier B, Dorval T, Chaput N, Andr\u00e9 F, Caby MP, Novault S, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med. 2005;3(1):10.","journal-title":"J Transl Med"},{"key":"2222_CR215","unstructured":"ModernaTX I. Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies 2025 [updated 2025 Aug 15. ClinicalTrials.gov Identifier: NCT03739931]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03739931?cond=NCT03739931%20&viewType=Table&rank=1"},{"key":"2222_CR216","unstructured":"Florida Uo. Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization 2026 [updated August 10, 2026. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05264974?cond=NCT05264974&viewType=Table&rank=1"},{"key":"2222_CR217","unstructured":"Genentech I. A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors 2026 [updated June 8, 2026. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03289962?cond=NCT03289962&viewType=Table&rank=1"},{"key":"2222_CR218","unstructured":"Assistance Publique HdP. Local Immunomodulation After Radiofrequency of Unresectable Colorectal Liver Metastases (LICoRN-01) 2025 [updated 2025 Apr 06. ClinicalTrials.gov Identifier: NCT04062721]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04062721?cond=NCT04062721%20&viewType=Table&rank=1"},{"key":"2222_CR219","unstructured":"ClinicalTrials.gov. Dendritic Cell Activating Scaffold in Melanoma. ClinicalTrialsgov. 2025."}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02222-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-026-02222-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02222-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:03:36Z","timestamp":1790093016000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-026-02222-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":219,"alternative-id":["2222"],"URL":"https:\/\/doi.org\/10.1007\/s13346-026-02222-6","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"15 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"<b>Declarations<\/b>"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"<b>Declarations<\/b>"}}]}}